Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study

20211,056 citationsJournal Article

Authors

Good health and well-being

Published in: The Lancet Oncology

Volume 22, Issue 7, pp. 977-990

Field-Weighted Citation Impact: 68.46